aviesan

ITMO Cancer

CEA · CHRU · CNRS · CPU · INRA · INRIA · INSERM · INSTITUT PASTEUR · IRD

ARIIS · CDEFI · CIRAD · EFS · FONDATION MÉRIEUX · INERIS · INSTITUT CURIE · INSTITUT MINES-TÉLÉCOM · IRBA · IRSN · UNICANCER

The theme-based multi-organization institute for Cancer (ITMO Cancer) aims to federate all research teams working on cancer diseases, regardless of their associated supervisory bodies. ITMO Cancer thus aims to submit concrete actions to improve the performance and competitiveness of French research, to ensure proper coordination between all bodies and institutions involved in cancer research, to lead consultation, and facilitate interdisciplinary exchanges in the cancer community.

800 research teams

6,000 researchers, lecturers, engineers and technicians from universities, hospitals, EPST and institutes

40,196 articles during 2011 to 2015 period

(Source Cellule Mesures, indicateurs, bibliométrie, Inserm 2016)

7th world rank of publications in the field

(Source Cellule Mesures, indicateurs, bibliométrie – Inserm 2016)

4th world rank of TOP 1% highly cited papers

(Source Cellule Mesures, indicateurs, bibliométrie – Inserm 2016)

ITMO CANCER STRATEGIC CHALLENGES

Multidisciplinary Basic Reasearch

- Studying the role of the non-coding genome in tumo rigenesis
- Developing knowledge of the protein and metabolic characteristics of cancer cells and their environment
- Pursuing understanding of cancer mechanisms, adaptive tumour dynamics, genetic and non-genetic plasticity
- Deciphering and understanding the role of microenvironment, describing the early stages of the anti-tumour immune response
- Understanding dormancy and resistance mechanisms
- Pursuing identification of risk factors: Genetics - Environment - Nutrition
- Studying cancer through evolution, including early, pre-neoplastic and possibly reversible stages



Emergence of mesenchymal tumor cells (in green) following the transformation of mammary epithelial cells (in red)
Alain Puisieux © Inserm

2018/01

ITMO scientific experts

Executive team

Director : Christine CHOMIENNE (Inserm, INCa)

Deputy Director : Alain EYCHENE (CNRS)

Assistant Director : Muriel ALTABEF (Aviesan)

Expert committee

- François BERGER (CEA)
- Jean-Paul BORG (Inserm)
- Irène BUVAT-GUILLEMET (CEA)
- Jean-Yves CAHN (CNRC)
- Salem CHOUAIB (Inserm)
- Jean CLAIRAMBAULT (Inserm, INRIA)
- Jacqueline CLAVEL (Inserm CESP)
- Yvan DE LAUNOIT (CNRS)
- Olivier DELATTRE (Inserm)
- Robin FAHRAEUS (Inserm)
- Jacqueline GODET (LNCC)
- Annick HAREL-BELLAN (CNRS)
- Claude LECLERC (Institut Pasteur)
- Fabrice PIERRE (INRA)
- Ariel SAVINA (ARIIS)
- Eric SOLARY (IGR)

Translational and Clinical Research

- Putting the patient as a pivotal actor of research
- Developing and diversifying animal models and their comparison; refining preclinical models to validate therapies and understand the side effects
- Developing alternative models
- Facilitating the drug design and repositioning of the old molecules
- Promoting new biomarkers for early diagnosis and follow-up (prediction of relapse/resistance, toxicity of treatments including immunotherapy)
- Developing sensitive, precise and reproducible technologies
- Developing stratification methods to predict clinical benefit and to select patients responding to treatment

Promotion and support of research work

- Producing quality and reproducible data and results, with emphasis on the quality of information and its representativeness rather than on number
- Highlighting researchers work on the basis of its quality and utility rather than its quantity
- Promoting transdisciplinary training at doctoral school level, encouraging interdisciplinary vocations, developing continuous training dedicated to cancer research

Download full Strategic Challenges on:
https://itcancer.aviesan.fr



Fragments of cancer cells internalized by dendritic cell.
Jenny Valladeau © Inserm